DS
FBRX icon

David Shaw’s Forte Biosciences FBRX Stock Holding History

David Shaw’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-851
Closed -$31K – 5451
2022
Q1 		$31K Buy
+851
New +$32.2K ﹤0.01% 5260
2021
Q3 		– Sell
-1,750
Closed -$1.47M – 5033
2021
Q2 		$1.47M Buy
1,750
+752
+75% +$678K ﹤0.01% 3232
2021
Q1 		$855K Buy
+998
New +$817K ﹤0.01% 3223
2020
Q1 		– Sell
-169
Closed -$34K – 4025
2019
Q4 		$34K Sell
169
-137
-45% -$31K ﹤0.01% 3907
2019
Q3 		$76K Buy
306
+240
+364% +$364K ﹤0.01% 3711
2019
Q2 		$166K Sell
66
-279
-81% -$827K ﹤0.01% 3497
2019
Q1 		$1.41M Buy
345
+247
+252% +$954K ﹤0.01% 2392
2018
Q4 		$301K Buy
+98
New +$422K ﹤0.01% 3343

Other funds holding FBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

David Shaw's FBRX Position: Q2 2022 in Review

David Shaw sold out of Forte Biosciences (FBRX) in Q2 2022, closing a stake of 851 shares — an estimated $31K sold.

David Shaw first reported a position in FBRX in Q4 2018 and held it in 8 quarters. The position peaked at $1.47M in Q2 2021. 39 funds tracked by Wall St. Rank hold FBRX as of Q2 2022.

  • David Shaw reported no remaining Forte Biosciences position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 851 Forte Biosciences shares in Q2 2022, an estimated $31K.
  • David Shaw first reported a position in Forte Biosciences in Q4 2018 and held it in 8 quarters.
  • David Shaw's Forte Biosciences position peaked at $1.47M in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.